Scholarlink

<p>Neuropathic pain (NP) is a chronic and debilitating condition characterized by hyperalgesia and allodynia, often resulting from nerve injury. Mesenchymal stem cells (MSCs) and their secretomes have shown promise in modulating inflammation and reducing NP symptoms. This study investigates the therapeutic effects of MSC-conditioned medium (MSC-CM) on NP in a rat model of chronic constriction injury (CCI) of the sciatic nerve. Thirty-two male Wistar rats were randomly assigned to four groups: Sham, CCI, DMEM (Vehicle), and CM-treated groups. The vehicle and MSC-CM (1&#xa0;mL) were administered intraperitoneally 1&#xa0;day after surgery and on postoperative days 7 and 11. Behavioral assessments of mechanical allodynia (von-Frey test), thermal hyperalgesia (hot plate test), and thermal allodynia (acetone test) were performed on days − 1 and postoperative days 3, 6, 9, 12, and 15. Glial activation markers GFAP and Iba1 were measured in the lumbar spinal cord using real-time PCR at the end of the study. Behavioral tests indicated significant NP development in CCI and vehicle-treated rats from days 3 to 15, while MSC-CM treatment delayed symptom onset to day 6 and significantly reduced pain by day 15. Molecular analysis revealed elevated GFAP and Iba1 expression in CCI rats, which was significantly reduced in MSC-CM-treated rats, suggesting decreased glial activation. MSC-CM administration attenuated NP symptoms and reduced glial cell activation, likely through anti-inflammatory mechanisms. This approach may offer a safer alternative to stem cell transplantation for managing NP.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Mesenchymal stem cell-conditioned medium mitigates neuropathic pain by suppressing glial activation in a chronic constriction injury model

  • 期刊论文

  • 发表日期：

    2025年7月1日

查看全文
  • Mohammad-Shafi Mojadadi,
  • Jahan Keyvanlou,
  • Murtaza Haidary,
  • Bahareh Amin,
  • Marzieh Kafami,
  • Samad Nazemi

摘要

Neuropathic pain (NP) is a chronic and debilitating condition characterized by hyperalgesia and allodynia, often resulting from nerve injury. Mesenchymal stem cells (MSCs) and their secretomes have shown promise in modulating inflammation and reducing NP symptoms. This study investigates the therapeutic effects of MSC-conditioned medium (MSC-CM) on NP in a rat model of chronic constriction injury (CCI) of the sciatic nerve. Thirty-two male Wistar rats were randomly assigned to four groups: Sham, CCI, DMEM (Vehicle), and CM-treated groups. The vehicle and MSC-CM (1 mL) were administered intraperitoneally 1 day after surgery and on postoperative days 7 and 11. Behavioral assessments of mechanical allodynia (von-Frey test), thermal hyperalgesia (hot plate test), and thermal allodynia (acetone test) were performed on days − 1 and postoperative days 3, 6, 9, 12, and 15. Glial activation markers GFAP and Iba1 were measured in the lumbar spinal cord using real-time PCR at the end of the study. Behavioral tests indicated significant NP development in CCI and vehicle-treated rats from days 3 to 15, while MSC-CM treatment delayed symptom onset to day 6 and significantly reduced pain by day 15. Molecular analysis revealed elevated GFAP and Iba1 expression in CCI rats, which was significantly reduced in MSC-CM-treated rats, suggesting decreased glial activation. MSC-CM administration attenuated NP symptoms and reduced glial cell activation, likely through anti-inflammatory mechanisms. This approach may offer a safer alternative to stem cell transplantation for managing NP.